Last reviewed · How we verify
NCT07202559
Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy
NA trial testing Indometacin suppository in Pancreatitis, Chronic in 1,250 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 1,250 |
| Start date | 13 October 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 10 locations across China |
Drugs / interventions tested
- Indometacin suppository — full drug profile →
- Lactated ringers solution — full drug profile →
- Normal Saline
Conditions studied
- Pancreatitis, Chronic — all drugs for Pancreatitis, Chronic →
- Pancreatitis, Acute — all drugs for Pancreatitis, Acute →
- Pancreatic Duct Stones — all drugs for Pancreatic Duct Stones →
Sponsor
Changhai Hospital
Who can join
Adults 18 to 85, any sex, with Pancreatitis, Chronic or Pancreatitis, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone. The study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin. The trial will be conducted at multiple centers, ensuring a broad and diverse patient population. The primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure. This study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07202559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatitis, Chronic
Currently open trials in the same condition.
- NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
- NCT06729996 — Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus · Phase 2 · recruiting
- NCT06549725 — Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pa · NA · recruiting
- NCT06330441 — Pancreatic Cancer Screening in a Population at High Risk · NA · recruiting
- NCT03260387 — A Prospective Observational Study of TPIAT · active not recruiting
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07202559 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07202559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing